Overview

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B

Status:
Completed

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

Summary

This primary objectives of this study are to compare the efficacy, safety, and tolerability of tenofovir disoproxil fumarate (TDF) versus adefovir dipivoxil (ADV) for the treatment of pre-core mutant chronic hepatitis B. Participants will receive TDF or ADV for 48 weeks (double-blind). After 48 weeks, eligible participants switched to open-label TDF for up to 480 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Adefovir
Adefovir dipivoxil
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Tenofovir